Technical Report abstract


Nature Medicine 14, 343 - 349 (2008)
Published online: 24 February 2008 | doi:10.1038/nm1691

Noninvasive assessment of cancer response to therapy

Zhaozhong Han1, Allie Fu1, Hailun Wang1,2, Roberto Diaz1, Ling Geng1, Halina Onishko1 & Dennis E Hallahan1,2,3,4

Top

Rapid assessment of cancer response to a therapeutic regimen can determine efficacy early in the course of treatment. Although biopsies of cancer can be used to rapidly assess pharmacodynamic response, certain disease sites are less accessible to repeated biopsies. Here, we simultaneously assess response in all sites of disease within days of starting therapy by use of peptide ligands selected for their ability to discern responding from nonresponding cancers. When conjugated to near-infrared imaging agents, the HVGGSSV peptide differentiates between these two types of cancer. Rapid, noninvasive assessment of the pharmacodynamic response within cancer promises to accelerate drug development and minimize the duration of treatment with ineffective regimens in cancer patients.

Top
  1. Department of Radiation Oncology, School of Medicine, Vanderbilt University, 1301 22nd Avenue South, B902 TVC, Nashville, Tennessee 37232, USA.
  2. Department of Cancer Biology, School of Medicine, Vanderbilt University, 1301 22nd Avenue South, B902 TVC, Nashville, Tennessee 37232, USA.
  3. Department of Biomedical Engineering, School of Medicine, Vanderbilt University, 1301 22nd Avenue South, B902 TVC, Nashville, Tennessee 37232, USA.
  4. Vanderbilt-Ingram Cancer Center, 1301 22nd Avenue South, B902 TVC, Nashville, Tennessee 37232, USA.

Correspondence to: Dennis E Hallahan1,2,3,4 e-mail: dennis.hallahan@vanderbilt.edu



MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

Highlights

Clinical Pharmacology & Therapeutics News and Views


Extra navigation

Subscribe to Nature Medicine

Subscribe

Open Innovation Challenges

naturejobs

ADVERTISEMENT